Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21635151 | 0.98 | CYP1A2 (0.48) | CYP1A2CYP2D6MAPTKMT2AHDAC3 | |
| Hydrochloric Acid SCHEMBL21635150 | 0.98 | CYP1A2 (0.48) | CYP1A2CYP2D6MAPTKMT2AHDAC3 | |
| SCHEMBL21484936 | 0.82 | KCNN4 (0.58) | CYP1A2CYP2D6MAPTKMT2AHDAC3 | |
| SCHEMBL23868362 | 0.82 | KCNN4 (0.58) | CYP1A2CYP2D6MAPTKMT2AHDAC3 | |
| SCHEMBL23797835 | 0.82 | KDM4E (0.42) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| Hydrochloric Acid SCHEMBL28909493 | 0.81 | KCNN4 (0.56) | CYP1A2CYP2D6MAPTKMT2AHDAC3 | |
| Hydrochloric Acid SCHEMBL23855523 | 0.81 | KCNN4 (0.56) | CYP1A2CYP2D6MAPTKMT2AHDAC3 | |
| SCHEMBL11480581 | 0.81 | HDAC3 (0.48) | CYP1A2CYP2D6MAPTKMT2AHDAC3 | |
| SCHEMBL8922875 | 0.81 | HDAC3 (0.48) | CYP1A2CYP2D6MAPTKMT2AHDAC3 | |
| SCHEMBL23797844 | 0.80 | CA1 (0.51) | MAPTKMT2ARECQLMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956878-A | Perovskite layer manufacturing method, perovskite battery, battery assembly and photovoltaic system | 浙江爱旭太阳能科技有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117956878-A | Perovskite layer manufacturing method, perovskite battery, battery assembly and photovoltaic system | 浙江爱旭太阳能科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20080227790-A1 | Pyridazinone Derivatives and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| EP-1716123-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2005075437-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-4389415-A | ALPHA-METHYL-P-TYROSINE, HYDRAZINO PHENYLPROPIONIC ACID | MERCK & CO., INC. (US) | 1983-06-21 | — | — | US | disclosed |
| US-4170654-A | Antihypertensive compositions containing N-heterocyclicalanines and α- | MERCK & CO., INC. (US) | 1979-10-09 | — | — | US | disclosed |
| EP-0003353-A1 | A pharmaceutical composition for oral administration for treating hypertension | MERCK & CO. INC. (US) | 1979-08-08 | — | — | EP | disclosed |
| US-4163054-A | PHENYL HYDRAZINO SUBSTITUTED PROPIONIC ACID DECARBOXYLASE INHIBITOR AND GUANETHIDINE | MERCK & CO., INC. (US) | 1979-07-31 | — | — | US | disclosed |
| US-4160835-A | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid | MERCK & CO., INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4160835-A | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid | MERCK & CO., INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4156734-A | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid | MERCK & CO., INC. (US) | 1979-05-29 | — | — | US | disclosed |
| US-4086354-A | TRIMETHAPHAN CAMSYLATE OR CLONIDINE WITH A HYDRAZINO PHENYL SUBSTITUTED PROPIONIC ACID DECARBOXYLASE INHIBITOR | MERCK & CO., INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4055645-A | HYDRALAZINE AND A HYDRAZINO PHENYL PROPIONIC ACID | MERCK & CO., INC. (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | CYP1A2 2894/4885CYP2D6 3905/4885MAPT 2314/4885 |
| US-20080227790-A1 | Pyridazinone Derivatives and their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE5A | CYP1A2 172/4885CYP2D6 142/4885MAPT 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.